TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

MUVON Therapeutics Appoints Dr. Christine Günther as Chief Technology Officer

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Dr. Deana Mohr
MUVON Therapeutics Appoints Dr. Christine Günther as Chief Technology Officer

MUVON Therapeutics announced positive Phase 2 clinical trial results for a novel muscle precursor cell therapy treating stress urinary incontinence, demonstrating high statistical significance and an 87% responder rate. The company also appointed Dr. Christine Günther as Chief Technology Officer to advance their regenerative medicine platform.

Insights
DHR   neutral

Listed as a key market player with potential growth opportunities in virtual biopsy technologies


EVO   neutral

Mentioned as a previous workplace for Dr. Günther with no specific company performance details